EGFR and familial pancreatic carcinoma: Therefore, EGFR and ERBB2 differentially impact ERBB signaling during pancreatic cancer tumorigenesis, highlighting the need to consider patient’s specific characteristics of ERBB signaling to optimize therapeutic treatment.